COLUMVI Patent Protection Prolonged: FDA's Usual Suspects
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for COLUMVI, a human biological product, so its patent can be extended. This helps the company behind COLUMVI get extra time to protect their invention before generic versions can appear. If you’re involved in drug patents or healthcare, this timing update matters for future market competition and innovation.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patent-Extension Step Opened for COLUMVI
The FDA has determined the regulatory review period for COLUMVI, a human biological product, so the company can submit applications to the U.S. Patent and Trademark Office to seek a patent extension that claims that product. This notice documents that formal step in the patent-extension process.
Timing Update Relevant to Market Competition
The FDA's determination affects timing for COLUMVI's patent-extension process, which the notice says gives the company extra time to protect the invention before generic versions can appear. If you work in drug patents, pharmaceuticals, or healthcare, this timing update is relevant to future market competition and innovation related to that product.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Previous / Next Documents
Previous: 2025-11320 — Determination of Regulatory Review Period for Purposes of Patent Extension; TRUQAP
The FDA has officially set the review period for TRUQAP, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive and profitable.
Next: 2025-11322 — Determination of Regulatory Review Period for Purposes of Patent Extension; BREYANZI
The FDA has officially set the review period for BREYANZI, a special medicine made from human cells. This means the company can ask for extra time on their patent to protect their invention. If approved, this could give them more exclusive rights before others can copy it, affecting when generic versions might appear and potentially impacting market competition and profits.